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ABSTRACT
DNA interstrand crosslinks (ICLs) represent a severe
formofdamagethatblocksDNAmetabolicprocesses
andcanleadtocelldeathorcarcinogenesis.Therepair
ofDNAICLsinmammalsisnotwellcharacterized.We
have reported previously that a key protein complex
of nucleotide excision repair (NER), XPA-RPA, recog-
nizesDNAICLs.Wenowreporttheuseoftriplextech-
nologytodirectasite-specificpsoralenICLtoatarget
DNAsubstratetodeterminewhetherthehumanglobal
genome NER damage recognition complex, XPC-
hHR23B, recognizes this lesion. Our results demon-
strate that XPC-hHR23B recognizes psoralen ICLs,
which have a structure fundamentally different from
otherlesionsthatXPC-hHR23Bisknowntobind,with
high affinity and specificity. XPC-hHR23B and XPA-
RPA protein complexes were also observed to bind
psoralenICLssimultaneously,demonstratingnotonly
that psoralen ICLs are recognized by XPC-hHR23B
alone, but also that XPA-RPA may interact cooperat-
ively with XPC-hHR23B on damaged DNA, forming a
multimeric complex. Since XPC-hHR23B and XPA-
RPA participate in the recognition and verification of
DNAdamage,theseresultssupportthehypothesisthat
interplay between components of the global genome
repairsub-pathwayofNERiscriticalfortherecognition
of psoralen DNA ICLs in the mammalian genome.
INTRODUCTION
Most bulky DNA lesions are processed by the nucleotide
excision repair (NER) pathway, which is composed of two
sub-pathways: transcription coupled repair (TCR) and global
genome repair (GGR). Lesions that inhibit DNA transcription
are believed to be the principle targets of the TCR pathway.
Experimental evidence has shown that RNA Pol II progression
along transcribed DNA is sensitive to the presence of DNA
damage, leading to the hypothesis that interruption of RNA
Pol II processivity could serve as the initiating signal for TCR
(1,2). Other constituents of this pathway (such as Cockayne
Syndrome Group A and B proteins) may also assist in the
identiﬁcation of DNA damage (3–7). The GGR sub-
pathway of NER is believed to be responsible for detecting
and repairing bulky DNA lesions over the entire genome with
the exception of those genes undergoing active transcription.
Although NER has been extensively studied, it is still debat-
able exactly which proteins are responsible for recognition of
speciﬁc lesions in GGR and TCR since a number of different
proteins, including Xeroderma pigmentosum protein Group C-
human homolog of RAD23B (XPC-hHR23B), replication
protein A (RPA) and X.pigmentosum protein Group A (XPA),
each bind to many DNA lesions that are substrates for NER
[reviewed in (8)].
Among the many different kinds of DNA damage, DNA
interstrand crosslinks (ICLs) are among the most detrimental
to DNA metabolism and are lethal in repair deﬁcient proka-
ryotic and eukaryotic cells (9). Both NER and homologous
recombination (HR) mechanisms are involved in repairing
DNA ICLs in bacteria and yeast (10–12), but the mechanisms
of repair of crosslinked DNA in mammalian cells are not well
characterized. A number of crosslinking agents, including the
psoralen family of intercalating, photoactivatable DNA dam-
aging agents, are available for the study of the repair of DNA
ICLs. Following irradiation with ultraviolet-A (UVA) light,
psoralen molecules form DNA crosslinks between thymines
on opposing strands of duplex DNA. Psoralen plus UVA
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doi:10.1093/nar/gki610(PUVA) therapy has been effectively utilized as a treatment
for psoriasis and cutaneous T-cell lymphoma, primarily due to
its ability to induce DNA ICLs that result in the inhibition of
DNA metabolism, induction of DNA mutations and cellular
toxicity (9,13). The preferred psoralen crosslinking site is a 50-
TpA, yet psoralens demonstrate minimal sequence speciﬁcity
when intercalating into the DNA. DNA triplex technology has
been successfully employed as a means to target psoralen in a
site-speciﬁc manner to generate a single, unique DNA cross-
link (14–16).This speciﬁcityis accomplished by conjugatinga
psoralen molecule to a triplex-forming oligonucleotide (TFO)
designed to bind with high afﬁnity and speciﬁcity, via Hoog-
steen or reverse-Hoogsteen hydrogen bonds, to a purine-rich
triplex recognition sequence on a target DNA duplex
[reviewed in (17)]. Targeting DNA damage via triplex forma-
tion has been used successfully in vitro and in vivo to induce
site-speciﬁc DNAmutations,DNArecombinationandtostudy
DNA–protein interactions at a speciﬁc site (17–22). We have
previously demonstrated that DNA damage recognition pro-
teins, including the NER proteins RPA and XPA, will bind to
triplex DNA substrates containing a single psoralen ICL (22).
Although both RPA and XPA likely play roles in detecting
DNA lesions (including DNA ICLs), there is very compelling
evidence suggesting that XPC-hHR23B is the principle dam-
age recognition factor in GGR [reviewed in (8) and references
therein]. Because of the critical role that XPC-hHR23B
appears to play in identifying DNA damage, we were inter-
ested in whether XPC-hHR23B would recognize a complex
lesion such as a TFO-directed psoralen-DNA ICL.
In this work the capacity of XPC-hHR23B, or XPC-
hHR23B in combination with XPA-RPA, to recognize a
unique TFO-directed psoralen-interstrandcrosslink (Tdp-ICL)
on a DNA substrate was investigated. Previously, others have
shown that XPC-hHR23B recognizes substrates containing
cis-platin-DNA intrastrand-crosslinks (23–26) and psoralen-
monoadducted DNA (27). Our results provide the ﬁrst demon-
stration that the human recombinant XPC-hHR23B protein
complex interacts with a Tdp-ICL with high afﬁnity and spe-
ciﬁcity. XPC-hHR23B was alsoobservedtobindto complexes
formed between psoralen damaged DNA and the XPA-RPA
NER recognition complex. At low XPA-RPA concentrations,
XPC-hHR23B and XPA-RPA compete for binding to the
lesion, but at higher RPA concentrations XPC-hHR23B and
XPA-RPA bound a damaged DNA substrate together to form a
high molecular weight multimeric complex. Our observations
implicate human XPC-hHR23B in the recognition of DNA
ICLs and demonstrate a possible positive interaction between
XPC-hHR23B and XPA-RPA in the recognition of these
lesions. Thus, these data support a role for the GGR sub-
pathway of NER in the recognition of Tdp-ICLs in the
mammalian genome.
MATERIALS AND METHODS
Oligonucleotides
Synthetic duplex targets for TFO binding from the APRT and
pSupFG1 triplex target sites were constructed as described
previously (22). pTFO1 (19mer) binds to the corresponding
19 bp polypurine site in the APRT-derived duplex (37 bp)
target and pTFOc is a 19 base scrambled oligonucleotide
that does not bind the APRT target (16). pAG30 (30mer)
forms a triplex DNA structure on a 30 bp polypurine site
on the 57-bp pSupFG1-derived sequence and pSCR30 is a
30 base scrambled control oligonucleotide (22). TFOs were
synthesized with a 50-psoralen derivative, HMT, (2-[40
(hydroxymethyl)-4,50,8-trimethylpsoralen]-hexyl-1-O-(2-cya-
noethyl)-N,N-diisopropyl)-phosphoramidite) by the Midland
Certiﬁed Reagent Company, Inc. (Midland, TX). Duplexes
were 50 end-labeled by the transfer of
32P from
[g-
32P]dATP with T4 polynucleotide kinase and puriﬁed
by 12% PAGE, electroeluted and concentrated via Centricon
centrifugal ﬁltration devices (Millipore, Bedford, MA). DNA
concentration was determined by UV absorbance at 260 nm.
Tdp-ICL formation
Triplex substrates were generated by incubating radiolabeled
duplex targets with psoralen-conjugated TFOs in a triplex
binding buffer [10 mM Tris–HCl, pH 7.6, 10 mM MgCl2
and 10% (v/v) glycerol] at 37 C for 16 h. Samples were then
irradiated with 1.8 J/cm
2 of UVA light at 366 nm to induce
psoralen ICLs. Efﬁciency of crosslinking at the targeted
triplex-duplex junction was as high as 90%, as determined
by the quantiﬁcation of the crosslinked product by denaturing
PAGE using a phosphorimager (Figure 1). All Tdp-ICL sub-
strates were gel puriﬁed to remove free duplex DNA (unless
stated otherwise) prior to use.
Human recombinant proteins
The XPC-hHR23B-maltose-binding protein fusion protein
was expressed and puriﬁed in Sf9 or Hi-5 insect cells as
described previously (28,29). Recombinant XPA-maltose-
binding protein fusion protein was expressed in Escherichia
coli PR745 and puriﬁed as described previously (30). For
recombinant RPA, the three subunits were expressed by
co-infection of Sf9 insect cells and puriﬁed by Ni
2+-chelate
column chromatography as previously described (31).
DNA–protein binding assays
DNA–protein binding interactions were analyzed by electro-
phoretic mobility shift assays (EMSAs). Human recombinant
proteins, at varying concentrations, were incubated in binding
buffer [25 mM Tris–HCl, pH 7.6, 100 mM NaCl, 1 mM DTT,
5 mM EDTA, 100 mg/ml BSA, 0.01% NP-40 (v/v) and 10%
glycerol (v/v)] in a 20 ml reaction volume for 10 min at room
temperature (unless otherwise stated). Radiolabeled duplex or
triplex substrates were then added and incubated at 30 C for
20 min. In the sequential addition experiments, the protein
used at the static concentration was incubated with the
Tdp-ICL substrate for 10 min, then increasing concentrations
of the other protein were added. In the simultaneous experi-
ments, proteins were incubated together for 10 min at room
temperature in binding buffer, and then the Tdp-ICL substrate
was added. The DNA–protein samples were then electro-
phoresed through a 6% (37.5:1 acrylamide/bis-acrylamide)
native PAGE, containing 2.5% glycerol and buffered in 1·
TGE (25 mM Tris–HCl, 192 mM glycine and 1 mM EDTA).
Electophoresis was conducted at 4 C, 9 mA/cm for 3 h. Gels
were dried and DNA–protein complexes were visualized
by autoradiography and quantiﬁed using a phosphorimager.
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Kinetic assay
DNA–protein complexes were formed as described above,
except that incubations were carried out for <10 s, 1, 2 or
4 min. The shortest time point was deﬁned as the time required
to add protein(s) to the DNA substrate immediately prior to
loading the reaction on the native PAG at 4 C (actual incuba-
tion time of protein with DNA substrate was <10 s at 4 C).
Antibody super-shift assay
DNA–protein complexes were formed as described above.
Next, monoclonal antibodies directed against RPA (anti-
RPA34; Lab Vision, Fremont, CA) or the maltose-binding
protein tag on the human recombinant XPC-hHR23B
(anti-MBP; New England Biolabs, Beverly, MA) were
added to the DNA–protein complexes (1 mg/20 ml reaction)
and incubated at 30 C for 10 min. Following incubation, the
reactions were electrophoresed through a 4 or 5% (37.5:1
acrylamide/bis-acrylamide) native PAG in 1· TGE buffer at
4 C, 200 V for 4 h. Gels were dried and the separated com-
plexes were visualized by autoradiography and quantiﬁed
using a phosphorimager.
RESULTS
Formation of Tdp-ICLs
Figure 1A depicts the 37 bp APRT-TA target duplex for the
19 nt psoralen-conjugated oligonucleotides, pTFO1 (the spe-
ciﬁc TFO), and pTFOc (the control oligonucleotide that does
not bind the APRT-TA sequence). Psoralen photomodiﬁcation
efﬁciency was determined by incubating the psoralen-
modiﬁed TFOs with the radiolabeled target duplex, APRT-
TA, to allow triplex formation, followed by UVA irradiation
of the samples at 1.8 J/cm
2. The samples were then subjected
to denaturing PAGE (Figure 1B) and the crosslinked popula-
tion was quantiﬁed by phosphorimage analysis. Psoralen
crosslinked product (Tdp-ICL) was formed with high efﬁci-
ency (>85%),while theamountofcrosslinked productformed
with the control TFO, pTFOc represented less that 1% of the
population, demonstrating that pTFO1 is capable of support-
ing a high level of site-speciﬁc DNA ICL formation.
Recognition of Tdp-ICL substrate by the human
recombinant XPC-hHR23B protein complex
The XPC-hHR23B complexhas been proposed to be the initial
damage recognition factor in GGR, although XPA and RPA
have also been implicated [recently reviewed in (8)]. Since we
have shown previously that the XPA and RPA NER proteins
bind to Tdp-ICLs (22), we wanted to determine whether XPC-
hHR23B also interacts with these lesions. To address this
question, Tdp-ICLs were formed on
32P-end-labeled duplex
DNA substrates of different sizes (37 and 57 bp) and incubated
with increasing concentrations of human recombinant XPC-
hHR23B (0.13, 1.3 and 6.5 nM). XPC-hHR23B bound both
Tdp-ICL substrates, except at the lowest protein concentration
(data not shown). To determine whether the binding of the
Tdp-ICL by XPC-hHR23B was dependent on the triplex struc-
ture induced by the TFO, a similar binding experiment was
performed on a TFO-directed psoralen ICL (following
removal of the third strand TFO). The results indicated that
XPC-hHR23B does bind the psoralen ICL in the absence of
triplex formation, but with slightly lower afﬁnity (data not
shown).
XPC-hHR23B binds with high specificity to a Tdp-ICL
in a concentration dependent manner
It has been reported that XPC-hHR23B interacts with both
damaged and undamaged DNA (24,25,32,33). In order to
ascertain speciﬁcity of XPC-hHR23B binding to ICL-
damaged DNA, XPC-hHR23B’s afﬁnity for the Tdp-ICL sub-
strate was compared to its binding to an undamaged DNA
substrate. The Tdp-ICL substrate was incubated with increas-
ing concentrations of XPC-hHR23B (from 0 to 13 nM) and
recognition of the Tdp-ICL was detected at concentrations as
Figure 1. Electrophoretic analysis of photoadducts formed by pTFO1 on the
APRT-TA synthetic DNA duplex. (A) Sequence of the APRT-TA (37 bp)
synthetic duplex is shown with the 50-TpA psoralen crosslinking site boxed.
The psoralen-conjugated specific TFO, pTFO1, and the scrambled control,
pTFOc, are shown. (B) TFOs were incubated with a
32P-end-labeled APRT-
TADNAtargetduplex,thenUVA-irradiatedat1.8J/cm
2toallowformationof
a site-specificTdp-ICL.Crosslinkingefficiencywasdeterminedbydenaturing
15% PAGE and quantified by phosphorimage analysis. Diagramatic represen-
tations of Tdp-ICLs, monoadducted single-strand DNA and denatured duplex
are shown to the right of the figure. The label py stands for pyrimidine-rich
strand (top strand in Figure 1A) and pu for purine-rich strand (bottom strand in
Figure 1A).
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(Kapp) at a concentration of 6.5 nM (Figure 2, lane 11). A
separate binding titration (to saturation) experiment was also
conducted by incubating increasing concentrations of XPC-
hHR23B with the Tdp-ICL substrate until essentially 100% of
the substrate was bound (at 65 nM XPC-hHR23B; data not
shown).Throughoutthe rangeofproteinconcentrations tested,
the amount of unbound Tdp-ICL substrate decreased with
increasing concentrations of XPC-hHR23B, while the amount
of unbound duplex DNA did not change. Recombinant XPC-
hHR23B (at concentrations >6.5 nM) was observed to bind
the undamaged duplex DNA substrate, however phosphorim-
age analysis revealed that <1% of the available substrate was
bound at even the highest concentration (13 nM) of XPC-
hHR23B (data not shown). Separate experiments revealed
that the binding proﬁle of XPC-hHR23B to duplex DNA
plus a control psoralen-modiﬁed oligonucleotide (that does
not bind the duplex target site) was indistinguishable from
that seen for protein incubated with duplex DNA only, as
expected (data not shown). These results conﬁrm that XPC-
hHR23B speciﬁcally binds the Tdp-ICL substrate, and sup-
ports previous observations by othersthat XPC-hHR23B binds
undamaged duplex DNA, but at a lower level than its binding
to a damaged DNA substrate (24,25,32,33).
Interactions of Human Recombinant XPC-hHR23B and
XPA-RPA on Tdp-ICLs
We have previously demonstrated that both RPA and XPA can
bind to the Tdp-ICL substrate used in the experiments herein
and that XPA appeared to modify RPA’s interaction on these
lesions(22).Unique interactions amongXPC-hHR23B,TFIIH
and XPA on different types of DNA damage have also been
demonstrated (34–38). Thus, we were interested in the poten-
tial interactions of RPA and/or XPA with XPC-hHR23B on
a Tdp-ICL substrate. In addition, we wanted to investigate
whether the order in which the proteins were added to the
reaction would inﬂuence any interactions of the proteins on
these lesions. In these experiments the concentration of XPC-
hHR23B was held constant at 6.5 nM (Kapp concentration)
while increasing concentrations of RPA (0.45–23.0 nM)
and/or XPA (1.6–160 nM) were added to the reaction. In
other experiments, the amount of XPC-hHR23B was varied
(from 0.26 to 13.0 nM) while RPA and/or XPA were held
constant at concentrations of 4.5 and 160 nM, respectively.
As reported previously (22), XPA alone did not appear to shift
the Tdp-ICL substrate in gel-shift assays (Figure 6, lane 2).
Furthermore, recognition of the Tdp-ICL substrate by XPC-
hHR23B did not appear to be affected by XPA at any of the
concentrations tested, regardless of when it was introduced
into the reaction with XPC-hHR23B and DNA substrate
(data not shown). Interestingly, RPA and XPC-hHR23B did
appear toinﬂuence each other when both proteins were present
in the reaction (Figure 3A and B), with a biphasic dependence
on RPA concentrations. At low concentrations of RPA and
XPC-hHR23B, they each form simple complexes with the
Figure 3. XPC-hHR23B and RPA interact to recognize a Tdp-ICL substrate
to form a higher-order protein–DNA complex. Proteins were tested by both
(A) sequential and (B) simultaneous addition to the Tdp-ICL.For these experi-
ments XPC-hHR23B (Lanes 1–5) or RPA (lanes 6–10) were held steady at
Kapp concentration while the concentration of the other protein was varied. All
DNA–proteinreactionswereincubatedandseparatedbyEMSAasdescribedin
theexperimentalprocedures.Lane1:XPC-hHR23B(6.5nM)only.Lanes2–5:
XPC-hHR23B(6.5nM)andRPAat0.45,4.5,9.0or23.0nMrespectively.Lane
6: RPA (4.5 nM) only. Lanes 7–10: RPA (4.5 nM) and XPC-hHR23B at 0.26,
1.3, 6.5 or 13.0 nM, respectively. (*): indicates position of the higher order
protein complex.
Figure 2. Human recombinant XPC-hHR23B recognizes Tdp-ICLs with high
specificity and affinity. The psoralen-conjugated specific TFO, pTFO1, was
UVA-crosslinked to a
32P-end-labeled 37 bp APRT-TA DNA target duplex to
form a site-specific Tdp-ICL. Varying concentrations of human recombinant
XPC-hHR23B (at concentrations of 0, 0.13, 1.3, 3.3, 6.5 and 13.0 nM) were
incubated with
32P-end-labeled APRT-TA duplex (10 nM, lanes 1–6) or Tdp-
ICL (10 nM, lanes 7–12) for 20 min at 30 C. DNA–protein complexes were
electrophoretically separatedon a 6%nativePAGin 1· TGEbuffer for3hat 9
mA/cm at 4 C. The gel was dried and the bands were visualized by autoradio-
graphy and quantified via phosphorimaging to determine the apparent disso-
ciation constant (Kapp).
2996 Nucleic Acids Research, 2005, Vol. 33, No. 9damaged DNA, and compete with one another for binding to
DNA. At higher RPA concentrations (>9 nM), higher order
complexes are formed, when either XPC-hHR23B or RPA is
added sequentially, or when they are added simultaneously.
For example, a unique higher-order complex was detected
with a slower mobility than that of the XPC-hHR23B-DNA
complex [indicated by an asterisk, Figure 3A and B, compare
lanes 3–5] in the presence of both XPC-hHR23B and RPA.
This higher-order complex was initially observed when the
concentration of XPC-hHR23B was held constant (6.5 nM)
andRPAwasaddedataconcentrationof11.3nM(*,Figure3A
and B, lane 4). At protein concentrations of 6.5 and 23.0 nM
for XPC-hHR23B and RPA, respectively, the higher-order
complex (*, Figure 3A and B, lane 5) was calculated to rep-
resent nearly 50% of the bound substrate. A higher-order
complex was also seen when RPA was held steady at
4.5 nM and XPC-hHR23B was present at 6.5 and 11.3 nM,
but under these conditions it represented only a minor amount
of the total shifted substrate (*, Figure 3A and B, lanes 9 and
10). These results were observed regardless of whether the
proteins were added to the reaction sequentially (Figure 3A) or
simultaneously (Figure 3B). When the experiments described
above were performed with XPC-hHR23B and the XPA-RPA
complex (rather than RPA alone), the results were indistin-
guishable from those presented in Figure 3.
Since the observations made in Figure 3 were based on
changes in the protein concentration relative to each compo-
nent’s Kapp concentration, the binding of these proteins to the
Tdp-ICL substrate was also tested at equimolar concentra-
tions. Proteins were added (in 10-fold increments) at concen-
trations ranging from 0.01 to 10 nM and allowed to incubate
with the damaged DNA substrate. Similar to the results shown
in Figure 3, the higher-order complex was only observed in the
presence of high concentrations of RPA (10 nM) (data not
shown).
Kinetic analysis of XPC-hHR23B and XPA-RPA
recognition of a Tdp-ICL substrate
In order to determine the kinetic properties of XPC-hHR23B
with XPA and RPA on Tdp-ICLs, RPA (4.5 nM) and
XPC-hHR23B (6.5 nM) were incubated, independently or
together, for varying lengths of time with the radiolabeled
Tdp-ICL substrate. As shown in Figure 4, the results indicate
that RPA and XPC-hHR23B both interact with the damaged
DNA substrate rapidly, with apparent half-maximal binding
being achieved in less than four minutes for both XPC-
hHR23B (Figure 4, lane 7) and RPA (Figure 4, lane 4).
XPC-hHR23B bound  25% of the available damaged sub-
strate even at the <10 s time point (Figure 4, lane 5), compared
to RPA which bound <5% (Figure 4, lane 1). These results
suggest that XPC-hHR23B can bind to the Tdp-ICL substrate
more rapidly than is detectable by this assay. As expected,
based on the results shown in Figure 3, these concentrations
ofRPA(4.5nM)andXPC-hHR23B(6.5nM)resultedinonlya
minor formation of the higher-order product, as seen by the
presence of a faint band migrating above damaged DNA sub-
strate bound by XPC-hHR23B alone (Figure 4, lanes 9–12).
Surprisingly, incubation of both proteins with the DNA sub-
strate resulted in a slight increase in complex formation at the
<10 s time-point, compared to the amount of substrate bound
when incubated with the individual components (Figure 4,
compare lane 9 to lanes 1 and 5). The mechanism of this inter-
action is not clear and further investigations using techniques
with better time resolution are warranted.
XPC-hHR23B and XPA-RPA interact in the
recognition of Tdp-ICLs
The higher-order complex seen in Figure 3 migrates in the gel
at a position above that seen for either RPA or XPC-hHR23B
when bound to the Tdp-ICL substrate. The presence of both
XPC-hHR23B and RPA was conﬁrmed by antibody super-
shift assays using monoclonal antibodies directed against
the 34 kDa subunit of RPA or to the maltose-binding protein
tag present on the puriﬁed human recombinant XPC-hHR23B
protein complex. Both the anti-RPA34 and anti-MBP antibod-
ies were able to super-shift essentially 100% of the RPA-DNA
or XPC-hHR23B-DNA complex (Figure 5, lanes 2 and 4, res-
pectively). The presence of both XPC-hHR23B (at 6.5 nM)
and RPA, at both low (4.5 nM; Figure 5, lanes 5–8) and high
Figure 4. XPC-hHR23B demonstrates rapid binding to a Tdp-ICL substrate. RPA (4.5 nM, lanes 1–4), XPC-hHR23B (6.5 nM, lanes 5–8) or both proteins
(Lanes 9–12) were incubated with the Tdp-ICL substrate (10 nM) and subjected to EMSA analysis. Incubation times were carried out for <10 s (lanes 1, 5 and 9),
1 (lanes 2, 6 and 10), 2 (lanes 3, 7 and 11) or 4 min (lanes 4, 8 and 12).
Nucleic Acids Research, 2005, Vol. 33, No. 9 2997(23.0 nM; Figure 5, lanes 9–12) concentrations, on the Tdp-
ICL-protein shifted complex was conﬁrmed by super-shifting
by the antibodies. Formation of the higher-order complex (*)
was observed in both instances (Figure 5) but represented the
majority of the gel-shifted protein–DNA complexes when
RPA was present at high concentrations (23 nM; Figure 5,
lane 9). Addition of anti-MBP antibodies resulted in complete
loss of the complex (*) and the appearance of a super-shifted
product at both low (4.5 nM) and high (23.0 nM) concentra-
tions of RPA (*2, Figure 5, lanes 6and 10, respectively). In the
presence of 4.5 nM or 23 nM RPA, anti-RPA34 also super-
shifted the higher-order complex (*) to a position equivalent to
the anti-MBP super-shifted XPC-hHR23B-Tdp-ICL complex
(*1, Figure 5, lanes 7 and 11). Reappearance of the XPC-
hHR23B-Tdp-ICL complex was observed when the anti-
RPA34 antibody was added to the reaction in the presence
of high concentrations of RPA (23 nM; Figure 5, lane 11),
suggesting that the antibody may partially interfere with the
formation of the higher-order complex. In the presence of
4.5 nM RPA and both antibodies (Figure 5, lane 8), a unique
higher-order complex (*3) was observed to migrate slightly
abovethepositionofthesuper-shiftedbandinFigure5(lane6).
Using anti-RPA34 and anti-MBP with high concentrations of
RPA in the reaction with XPC-hHR23B and the Tdp-ICL
substrate resulted in a combination of banding patterns that
were observed in the other lanes; however, the higher-order
complex could be seen more intensely than the other bands
(*3, Figure 5, lane 12). The antibodies were speciﬁc as neither
demonstrated binding to the Tdp-ICL substrate alone nor the
non-antigen protein(datanotshown).Thesuper-shiftingofthe
higher-order complex by antibodies speciﬁc to either RPA or
recombinant XPC-hHR23B supports our conclusion that both
proteins may be able to cooperatively bind to the Tdp-ICL
substrate, thereby forming a unique ternary complex.
We have previously shown, using antibody super-shift
analyses, that XPA and RPA will form a ternary complex
on a Tdp-ICL substrate (22). Here, formation of a higher-
order complex was only seen in experiments that included
high concentrations of RPA (>9 nM) incubated with XPC-
hHR23B. XPA alone did not exhibit similar behavior when
incubated with XPC-hHR23B.To determine ifthere was inter-
play between XPC-hHR23B, XPA and RPA, these NER
components were incubated in various combinations and
concentrations with the Tdp-ICL substrate. XPC-hHR23B
was present at 6.5 nM (Figure 6, Lanes 1, 4, 5 and 10–12),
XPA was used either at 160 nM (Figure 6, lanes 2, 6, 8, 10 and
11) or 800 nM (Figure 6, lanes 4, 7, 9 and 12) and RPA was
included at concentrations of either 4.5 nM (Figure 6, lanes 3,
6, 7 and 10) or 23 nM (Figure 6, lanes 5, 8, 9, 11 and 12). The
results indicate that XPA (160 nM) alone did not shift the Tdp-
ICL substrate (Figure 6, lane 2), or alter the mobility of an
RPA-bound substrate at either 160 or 800 nM (Figure 6, com-
pare lane 3 with lanes 6 and 7, respectively), as expected from
our previously published results (22). Furthermore, the pres-
ence of XPA (160 or 800 nM) did not visibly alter the mobility
of the higher-order complex (*, Figure 6, lanes 11 and 12),
compared to reactions with XPC-hHR23B and RPA only
(*, Figure 6, lane 6). These results demonstrate that the experi-
mental outcome, when using the XPA-RPA complex and
XPC-hHR23B, is indistinguishable from those experiments
conducted with XPC-hHR23B and RPA only.
DISCUSSION
While unrepaired DNA damage threatens cell survival and
proliferation, repair can introduce deleterious mutations.
Figure 5. XPC-hHR23B and RPA are capable of simultaneously interacting
with a Tdp-ICL substrate. All reactions were incubated with the Tdp-ICL
substrate (10 nM) and protein, with or without monoclonal antibodies specific
forthe34kDasubunitofRPAortheMBPtagonthehumanrecombinantXPC-
hHR23B protein complex. All conditions were carried out as described in the
experimentalprocedures.RPA:4.5nM(lanes1,2,5–8)or23nM(lanes9–12).
XPC-hHR23B: 6.5 nM (lanes 3–12). Anti-RPA34:1mg (lanes 2, 7, 8, 11, 12).
Anti-MBP:1mg(lanes4,6,8,10,12).†: RPA-Tdp-ICLsuper-shiftedcomplex
also migrated at the same position as when Tdp-ICL was bound by XPC-
hHR23B. (*, *1, *2 and *3): see text for explanation.
Figure 6. The XPA-RPA protein complex interacts with XPC-hHR23B on the
Tdp-ICL in a similar fashion as RPA alone. All DNA–protein reactions were
incubatedandseparatedbyEMSAasdescribedintheexperimentalprocedures.
XPC-hHR23B was used at a single concentration of 6.5 nM (lanes 1, 4, 5, and
10–12).XPAwasusedattwodifferentconcentrations:160nM(lanes2,6,8,10
and 11) and 800 nM (lanes 3, 7, 9 and 12). RPA was also used at two con-
centrationsofeither4.5nM(lanes3,6,7and10)or23nM(lanes5,8,9,11and
12). *: ternary complex of XPC-hHR23B-XPA-RPA-Tdp-ICL.
2998 Nucleic Acids Research, 2005, Vol. 33, No. 9The nature and frequency of these mutations are functions of
the type of damage and the repair mechanisms that operate on
them. DNA repair pathways are conveniently categorized
according to the types of lesions with which they are associ-
ated, but there is growing evidence that there is considerable
overlap and ‘repair crosstalk’ between these pathways
[recently reviewed in (39)].
For example, both HR and NER participate in the removal
of DNA ICLs in bacteria and yeast (10–12,40), however the
mechanism of ICL repair in mammalian cells is not clear. Liu
et al. (41) demonstrated that repair of mammalian DNA ICLs
required members of the HR repair pathway since cells
deﬁcient in some of these proteins are highly susceptible to
crosslinking compounds. Furthermore, it was recently shown
that proteins from the mammalian mismatch repair (MMR)
pathway may also play a role in the error-free removal of DNA
ICLs (42,43). In addition, Wang et al. (44) demonstrated that
constituents of the NER pathway facilitate the repair of ICLs
in mammalian cells, but that the process occurred in a
recombination-independent, error-generating fashion. Many
different lines of evidence implicate the XPC-hHR23B protein
complex as the primary initiating factor for DNA damage
recognition in the GGR sub-pathway of NER [reviewed in
(8) and references therein]. In a number of studies it has
been demonstrated that the XPC-hHR23B protein complex
is the ﬁrst to bind damaged DNA and that XPA is not localized
to DNA damage unless XPC-hHR23B is already present at the
site of the lesion (24,45,46). The ﬁndings from those studies
implicate XPC-hHR23B as a crucial component needed to
initiate the repair of DNA damage that falls within the purview
of the GGR pathway.
The XPA-RPA complex was previously observed to recog-
nize psoralen-crosslinked triplex DNA substrates (22). In the
work described here, we have presented the ﬁrst biochemical
evidence that XPC-hHR23B recognizes psoralen-crosslinked
triplex DNA (Tdp-ICL) with high speciﬁcity and afﬁnity
(Figure 2). The recognition of the Tdp-ICL by XPC-hHR23B
occurred within seconds of encountering the substrate, sug-
gesting a very fast mechanism of recognition (Figure 4). A
novel ﬁnding in the work presented here was that XPC-
hHR23B (6.5 nM) and XPA (160 nM)-RPA (at concentrations
>9nM)wereable toform a uniqueternary complex (Figure3)
on the Tdp-ICL substrate, conﬁrmed by antibody super-shift
assay (Figure 5). Notably, incubation of both proteins
with antibodies speciﬁc to either human recombinant XPC-
hHR23B or RPA resulted in a complete loss of the
higher-order complex (*, Figure 5) and the formation of a
super-shifted complex with a lower mobility (*3, Figure 5,
lanes 8 and 12) than was observed with incubation of the
higher-order complex with either antibody alone. The
observed antibody-antigen speciﬁcity strongly suggests that
the uppermost super-shifted complex is indeed a complex
of XPC-hHR23B-XPA-RPA on the damaged DNA substrate,
representing a possible positive interaction between these pro-
teins. These results implicate the GGR sub-pathway of NER as
a possible mechanism for the removal of DNA ICLs in mam-
malian genomes. Although no direct protein–protein interac-
tion has been demonstrated between XPC-hHR23B and RPA,
it has been proposed that binding of XPC-hHR23B near a
region of DNA damage induces a conformational change
in the substrate and precipitates the formation of the NER
pre-incision complex (24,47). Consistent with these ﬁndings,
Reardon and Sancar (48,49) recently proposed that coopera-
tion between NER pre-incision proteins (XPC-hHR23B, RPA
and XPA) plus a kinetic proofreading function, supplied by
TFIIH, could explain the ability of the NER pathway to detect
and repair thymine dimers. They further hypothesized that
increased speciﬁcity is accomplished through the interplay
of proteins on neighboring or overlapping regions of DNA,
independent of the order in which the proteins bind the dam-
aged substrate, an idea that suggests a possible function for
the higher order complexes we have observed in the work
presented here.
Experiments using XPC-hHR23B and XPA (without RPA)
demonstrated that XPA by itself was not enough to inﬂuence
the recognition of the Tdp-ICL substrate by XPC-hHR23B
(Figure 6, lane 4). The interaction of XPC-hHR23B with
RPA (in the presence or absence of XPA) on ICL-containing
substrates was also seen in experiments involving combina-
tions of XPC-hHR23B, XPA and RPA at different concentra-
tions (Figure 6). Interestingly, our results differ from those
reported by You et al. (34) who showed that XPC-hHR23B
physically interacted with XPA but that addition of both XPA
and RPA displaced XPC-hHR23B from a substrate containing
a cis-platin intrastrand crosslink. In our work, XPC-hHR23B
and RPA competed for binding to the lesion at low concen-
trations of RPA but formed a complex on the damaged DNA
including both XPC-hHR23B and XPA-RPA at high concen-
trations of RPA; the concentrations of RPA required are not
inconsistent with a physiological role for this complex, given
the high levels of RPA in the nucleus. It is possible that the
types of complexes formed on the intrastrand crosslinks
studied by You et al. (34) may differ from those formed on
the ICLs studied here.
Wakasugi and Sancar (28) performed an experiment similar
to ours using high concentrations of RPA (100 nM) with XPC
(37 nM) on a single (6–4) photoproduct, but did not observe
any evidence of a positive interaction between these proteins.
Some possible reasons for this apparent discrepancy can be
given. First, the lack of a higher-order complex could be due to
their use of a substrate containing a different type of lesion, the
(6–4) photoproduct. Second, they used XPC at a concentration
that was <3-fold below that of RPA. In our experiments,
formation of the ternary complex was most favorable when
there was a 5-fold difference between the protein concentra-
tions, although moderate formation of the higher-order com-
plex could be seen with as low as a 3-fold difference in protein
concentrations (*, Figure 3A and B, compare lanes 3 and 5).
There have been a number of studies that have conﬁrmed
the formation of an XPA-RPA-DNA complex (22,28,34,
50,51), but to our knowledge, no one has reported the forma-
tion of a ternary complex between ICL-damaged DNA,
XPC-hHR23B, and RPA. The cellular concentrations of
XPC, RPA and XPA have been estimated at 4–8 · 10
4
(52), 2.4 · 10
5 (53) and 5 · 10
4 (54) molecules per cell,
respectively. We believe our experimental conditions reﬂect
the presumed ratio of these NER factors in eukaryotic cells,
thus supporting the possibility of an in vivo cooperative inter-
action between XPC-hHR23B and XPA-RPA in the recogni-
tion of psoralen-ICLs. The abundance of RPA suggests that
it may play a role in determining the sensitivity of cells to
DNA damage.
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